SCHEDULE: Nantahala Capital Management Discloses 7.45% Stake in Grace Therapeutics

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 1,654,393 shares, representing 7.45% of Grace Therapeutics, Inc.'s common stock.

Summary

• Nantahala Capital Management, LLC, and its managing members Wilmot B. Harkey and Daniel Mack, have filed a Schedule 13G, indicating their beneficial ownership of 1,654,393 shares of Grace Therapeutics, Inc. common stock.
• This holding represents 7.45% of the total outstanding shares as of September 30, 2026.
• The filing specifies that 1,178,203 of these shares may be acquired within sixty days through the exercise of convertible securities.
• Nantahala Capital Management, LLC is identified as an investment adviser, and Messrs. Harkey and Mack are filing as control persons of Nantahala.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not controlling stake by Nantahala Capital Management, LLC, without immediate implications for control changes.

Positives

• Nantahala Capital Management, LLC, a significant investment firm, has taken a notable stake in Grace Therapeutics, Inc., which could signal confidence in the company's future prospects.
• The potential acquisition of an additional 1,178,203 shares through convertible securities suggests a strategic long-term interest by Nantahala.

Negatives

• The filing does not disclose any negative financial performance or operational issues for Grace Therapeutics, Inc.

Risks

• The potential exercise of convertible securities could lead to dilution if not managed carefully by the company.
• While not explicitly stated as a risk in this filing, significant ownership by an activist investor like Nantahala could lead to pressure for strategic changes that may not align with current management's vision.

Future Outlook

The filing indicates that 1,178,203 shares may be acquired within sixty days through the exercise of convertible securities, suggesting a potential increase in Nantahala's stake.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. Nantahala Capital Management's filing suggests an active investment strategy within the biotechnology or therapeutics sector where Grace Therapeutics operates.

Stakeholder Impact

• Shareholders may see increased market interest in Grace Therapeutics due to the significant stake taken by Nantahala Capital Management.
• The potential exercise of convertible securities could impact the existing share structure.

Next Steps

• Nantahala Capital Management may acquire additional shares through the exercise of convertible securities within the next sixty days.

Key Dates

Recommendation

The filing indicates a significant investment by Nantahala Capital Management, but it does not provide enough information on Grace Therapeutics' performance or future prospects to warrant a buy or sell recommendation. The stake is substantial but not controlling, suggesting a 'hold' position pending further developments or disclosures from the company.

Keywords

Grace Therapeutics, Nantahala Capital Management, Schedule 13G, Beneficial Ownership, Investment Adviser, Convertible Securities, Shareholder